In a Q&A with Financier Worldwide Magazine, Frank Aquila, S&C’s Senior M&A Partner, discussed the state of M&A activity across healthcare and life sciences, and recent trends in deal volume and value. “Despite broader market volatility because of economic and political challenges, healthcare and life sciences remain among the most resilient sectors for M&A,” he said.
Frank also highlighted his confidence in the resilience and adaptability of dealmakers looking into 2026, despite the latest challenges of valuation gaps, regulatory delays and integration risk influencing deal strategy. “I expect deal activity to be strong, though shaped by ongoing regulatory oversight and macroeconomic dynamics such as interest rates and tariff policies,” he noted. “The key tests for dealmakers will be navigating political and pricing reforms, integrating technology effectively and managing cross-border complexities in an increasingly fragmented geopolitical environment.”
Read the article.